<- Go home

Added to YB: 2024-09-17

Pitch date: 2024-09-10

NTRA [bullish]

Natera, Inc.

+95.26%

current return

Author Info

No bio for this author

Company Info

Natera, Inc., a diagnostics company, provides molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Market Cap

$28.2B

Pitch Price

$118.79

Price Target

N/A

Dividend

N/A

EV/EBITDA

-91.38

P/E

-89.19

EV/Sales

12.92

Sector

Biotechnology

Category

growth

Show full summary:
Brown Capital Management Mid Company Fund Portfolio Holding: Natera, Inc.

NTRA: Diagnostic co using advanced DNA detection in blood tests. Leader in prenatal, cancer recurrence & transplant rejection tests. 25% rev to R&D. $15-20B cancer market opportunity. Unprofitable now but scaling & improving reimbursements. 20% 5yr rev CAGR expected. Large markets, innovation & clinical data support growth.

Read full article (1 min)